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Background: Developing predictive markers for hepatocellular carcinoma (HCC) is important, be-
cause many patients experience recurrence and metastasis. Epithelial to mesenchymal transition 
(EMT) is a developmental process that plays an important role during embryogenesis and also 
during cancer metastasis. Paired-related homeobox protein 1 (Prrx-1) is an EMT inducer that has 
recently been introduced, and its prognostic significance in HCC is largely unknown. Methods: 
Tissue microarray was constructed using surgically resected primary HCCs from 244 cases. Im-
munohistochemical staining of E-cadherin and Prrx-1 was performed. The correlation between E-
cadherin loss and Prrx-1 expression, as well as other clinicopathologic factors, was evaluated. 
Results: E-cadherin expression was decreased in 96 cases (39.4%). Loss of E-cadherin correlat-
ed with a higher recurrence rate (p < .001) but was not correlated with patient’s survival. Thirty-
two cases (13.3%) showed at least focal nuclear Prrx-1 immunoreactivity while all non-neoplastic 
livers (n = 22) were negative. Prrx-1 expression was not associated with E-cadherin loss, survival 
or recurrence rates, pathologic factors, or the Ki-67 labeling index. Twenty tumors that were posi-
tive for E-cadherin and Prrx-1 had significantly higher nuclear grades than the rest of the cohort (p 
= .037). In Cox proportional hazard models, E-cadherin loss and large vessel invasion were inde-
pendent prognostic factors for shorter disease-free survival. Cirrhosis and high Ki-67 index (> 
40%) were independent prognostic factors for shorter overall survival. Conclusions: Prrx-1 was 
expressed in small portions of HCCs but not in normal livers. Additional studies with a large num-
ber of Prrx-1-positive cases are required to confirm the results of this study.
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▒ ORGINAL ARTICLE ▒
Hepatocellular carcinoma (HCC) is one of the most lethal 
and relatively prevalent cancers worldwide, as well as in Korea. 
The Korean National Cancer Information Center estimates that 
over 2.2 per hundred thousand persons were killed by HCC in 
2013, which is the second most common cause of death by can-
cer in Korea.1 Although surgical resection is effective in cases of 
the incipient disease, even in early stages, a considerable num-
ber of patients experience recurrence and metastasis leading to a 
poor prognosis.2 Therefore, it is important to develop markers 
that indicate poor prognosis, and to provide stratified follow-up 
guidelines for clinicians.
Epithelial tumor metastasis can be described by a develop-
mental program called epithelial to mesenchymal transition 
(EMT), which plays crucial roles in embryonic development, in-
cluding mesoderm formation and migration of neural crest cells.3 
During metastasis, the tumor cells lose their epithelial property, 
gain migratory activity, disseminate through the blood stream, 
and finally, establish metastatic foci in distant organs.3
Paired-related homeobox protein 1 (Prrx-1; PRX-1) is a tran-
scription factor that has recently been found to induce EMT in 
embryogenesis, as well as in several cancers, including breast, 
pancreas, colon, and thyroid cancer.4-7 However, it has been in-
consistently reported on whether its upregulation or downregu-
lation is associated with poor prognosis. In colorectal and thy-
roid cancers, overexpression of Prrx-1 was associated with poor 
prognosis or worse histologic type.4,7 In comparison, in breast 
cancers and HCCs, downregulation of Prrx-1 was associated 
with poor prognosis.5,8
In this study, we used tissue microarray (TMA) to determine 
if the loss of E-cadherin is a prognostic marker for predicting 
early recurrence and poor survival rate. We surgically obtained 
244 cases of human HCC tissues in the Hanyang University 
Medical Center, Seoul and Guri hospitals. We examined Prrx-1 
expression in HCC using immunohistochemistry, and investi-
gated the relationship between its expression and loss of E-cad-
herin. We also worked to determine if expression of Prrx-1 could 
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be a prognostic marker to predict metastasis or poor survival 
rate, because it induces EMT and its significance is currently 
unknown. We also investigated the relationship between clini-
copathologic factors such as tumor size, vascular invasion, histo-
logic grade, and the Ki-67 index to explore the clinical signifi-
cances of E-cadherin and Prrx-1.
 MATERIALS AND METHODS
Patients and specimens
A total of 244 patients who underwent surgical resection for 
HCC from 1991 to 2013 at Hanyang University Medical Cen-
ter, Seoul and Guri hospitals were selected as subjects for this 
study. Medical records were reviewed to identify baseline clini-
cal information, clinical course, underlying etiology, and liver 
function status at the diagnosis. Histological review was per-
formed to determine stage, grade (Edmondson and Steiner’s 
grading system), vascular invasion, size of tumor, and multiplici-
ty. This study was conducted under review of the Institutional 
Review Board (IRB) of Hanyang University Guri Hospital (Code, 
2015-11-012).
TMA, immunohistochemistry, and interpretation
Representative tissue blocks were selected for TMA construc-
tion after histological review. For each case, a 2-mm single core 
was punched from the tumor but not from normal tissue. All 
immunostainings were performed using the automated system, 
Leica Bond III (Leica Biosystems, Nusslock, Germany) and 
Bond Polymer Refine Detection Kit (Leica Biosystems). E-cad-
herin antibody (mouse monoclonal, NCL-L-E-Cad, Novocastra, 
Newcastle upon Tyne, UK) was diluted at 1:25. Prrx-1 anti-
body (rabbit polyclonal, NBP2-13816, Novus Biologicals, Lit-
tleton, CO, USA) was diluted at 1:20. Ki-67 antibody (mouse 
monoclonal, NCL-L-Ki67-MM1, Novocastra) was diluted at 
A
C D E
B
Fig. 1. Immunohistochemical staining of E-cadherin and paired-related homeobox protein 1 (Prrx-1) in hepatocellular carcinomas. Represen-
tative photos of immunohistochemical staining in hepatocellular carcinomas. (A) E-cadherin decreased. (B) E-cadherin maintained. (C) Prrx-1 
negative. (D) Prrx-1 positive. (E) Prrx-1 negative, but cytoplasmic positive.
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1:200. TMA sections (4-μm-thick) were de-waxed, and the an-
tigen was retrieved with Bond Epitope Retrieval Solution 2 
(Leica Biosystems), then incubated with primary antibodies for 
60 minutes.
Two pathologists assessed E-cadherin staining into two cate-
gories as described previously;9 negative or faint membranous 
stained and moderate to strong membranous stained. The aver-
age E-cadherin stainability of HCC cells in each core was evalu-
ated. Prrx-1 staining was evaluated by its nuclear positivity as 
previously described.4 Cytoplasmic stained cases without nucle-
ar positivity for Prrx-1 were interpreted as negative because they 
were considered to be nonspecific cytoplasmic antibody entrap-
ping. Representative images of immunohistochemical staining 
are presented in Fig. 1. To determine whether the immunoex-
pression of Prrx-1 in HCCs was upregulated or lost, comparing 
to normal or cirrhotic liver, we performed Prrx-1 immunostain 
to two whole block sections and one TMA section that con-
tained 20 cores of normal liver tissue block obtained that were 
obtained from liver resections from traumatic liver laceration, 
or metastatic colon cancer. We stained one whole section from 
each of the three Prrx-1–positive HCCs and three Prrx-1–nega-
tive HCCs, to determine if the single TMA core was represen-
tative of the entire tumor’s Prrx-1 expression status. The cases 
were randomly selected from the cohort and all sections includ-
ed adjacent cirrhotic liver. Ki-67 immunostain was performed 
on TMA sections. The Ki-67 labeling index was calculated by a 
free image analyzing software, TMARKER v2.21625.10
Statistical analysis
We investigated the relationship between the loss of E-cad-
herin and clinicopathologic factors as well as survival time and 
recurrence. Expression of Prrx-1 was evaluated with the same 
method. Concordance of loss of E-cadherin and Prrx-1 expres-
sion was analyzed. We also correlated the expression with other 
markers to investigate whether those markers reflect aggressive 
pathologic features. The association between immunohistochem-
ical stain results and clinicopathologic parameters was analyzed 
using the chi-square test, Fisher exact test, and Mann-Whitney 
U test. Recurrence and survival rate was calculated by the Ka-
plan-Meier method, and the comparisons were made using the 
log-rank test. The Cox proportional hazard regression model 
was adopted to determine the prognostic impact of immuno-
histochemical results and other clinicopathologic parameters. 
For the Cox regression, high Ki-67 was defined as Ki-67 index 
over 40, by considering the cutoff values of previous studies.11,12 
For all calculations, differences at p < .05 were considered statis-
tically significant. All statistical calculations were performed 
using the R software ver. 3.1.0 (R Core Team 2014).
RESULTS
Clinicopathological characteristics
The clinicopathologic features are summarized in Table 1. 
The median age of the 244 patients was 56 years (range, 24 to 
87 years). One hundred eighty-three patients were male (75%), 
and 61 were female (25%). One hundred seventy-one patients 
had hepatitis B virus (HBV, 70.1%), and 16 had hepatitis C vi-
rus (HCV, 6.6%). Two patients had both HCV and HBV coin-
fection (0.8%). Twenty-five patients had no viral hepatitis but 
had a history of chronic alcohol intake without any apparent vi-
Table 1. Clinicopathologic characteristics of HCC patients (n = 244)
Parameter No. (%)
Age (yr)a 56 (24–87)
Sex (male:female) 183:61 (3:1)
Etiological factor
HBV 171 (70.1)
HCV 16 (6.6)
HBV + HCV 2 (0.8)
Alcohol 25 (10.2)
Unknown 30 (12.3)
Underlying disease
Chronic hepatitis 44 (18)
Cirrhosis 200 (82)
Child-Pugh class
A 230 (94.3)
B 14 (5.7)
AJCC stage
I 132 (54.1)
II 79 (32.4)
III 33 (13.5)
Tumor size (cm)a 3.5 (0.6–19.5)
Multiplicity (solitary/multiple)
Solitary 201 (82.4)
Multiple 43 (17.6)
Histologic grade
1, 2 109 (44.7)
3, 4 135 (55.3)
Small vessel invasion 94 (38.5)
Large vessel invasion 24 (9.8)
Recurrence rate (%)
1 Year 35.0
5 Years 65.3
Survival rate (%)
1 Year 87.4
5 Years 55.6
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C vi-
rus; AJCC, American Joint Committee on Cancer.
aMedian (range).
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ral etiology (10.2%). Thirty patients had neither viral hepatitis 
nor history of chronic alcoholic intake (12.3%). Cirrhosis was 
detected in 200 patients (82%). Child-Pugh classes were stage 
B in 14 patients (5.7%), while the others are stage A (94.3%). 
Regarding pathologic stage, 132 patients were stage I (54.1%), 
79 were II (33.4%), eight were IIIA (3.3%), 24 were IIIB (9.8%), 
and one was IIIC (0.4%). Median tumor size was 3.5 cm (range, 
0.6 to 19.5 cm). Two hundred one cases presented as a solitary 
tumor (82.4%) while the others presented as multiple tumors. 
Portal vein, hepatic vein, or their major branch involvement 
was detected in 45 patients (18.4%).
One hundred and six patients died during follow-up. Median 
survival time was 70.8 months (range, 1.3 to 287.7 months) 
and 5-year survival rate was 55.6%. In addition, 35% of cases 
showed a tumor recurrence within 1 year, and 65.3% under-
went recurrence within 5 years. The Kaplan-Meier method 
showed a significant difference in overall survival and disease-
free survival between stages I and II (p = .006, and p < .001, re-
spectively). However, those between stage II and stage III were 
not statistically significant (p = .450 and p = .106, respectively). 
Additionally, 3.9% of stage I patients experienced tumor recur-
rence within 1 year (n = 19), compared with 20.6% of stage II (n 
Table 2. Association between E-cadherin and Prrx-1 expression and clinicopathologic parameters in HCC patients (n = 244)
Parameter
E-cadherin
p-value
Prrx-1
p-value
Decreased (n = 96) Maintained (n = 148) Positive (n = 32) Negative (n = 212)
Age (yr)a 57 (31–77) 55 (24–87) .135b 60 (24–74) 55.5 (28–87) .161b
Sex (male:female) 74:22 (3.4:1) 109:39 (2.8:1) .650c 24:8 (3:1) 159:53 (3:1) >.990c
Etiology (%) .090d
HBV 59 (61.5) 112 (75.7) 20 (62.5) 151 (71.2) .501d
HCV 10 (10.4) 6 (4.1) 2 (6.2) 14 (6.6)
HBV + HCV 1 (1) 1 (0.7) 0 2 (0.8)
Alcohol 13 (13.5) 12 (8.1) 3 (9.4) 22 (10.8)
Unknown 13 (13.5) 17 (11.5) 7 (21.9) 23 (10.8)
Underlying disease (%) .048c .893d
Chronic hepatitis 11 (11.5) 33 (22.3) 5 (18.4) 39 (15.6)
Cirrhosis 85 (88.5) 115 (77.7) 27 (81.6) 173 (81.6)
Child-Pugh class .996c >.990d
A 91 (94.8) 139 (93.9) 30 (93.8) 200 (94.3)
B 5 (5.2) 9 (6.1) 2 (5.7) 12 (5.7)
AJCC stage .707c .399d
I 50 (52.1) 82 (55.4) 20 (62.5) 112 (52.8)
II 34 (35.4) 45 (30.4) 7 (21.9) 72 (34.0)
III 12 (12.5) 21 (14.2) 5 (15.6) 28 (13.2)
Multiplicity .406c .571c
Single 82 (85.4) 119 (80.4) 28 (87.5) 173 (81.6)
Multiple 14 (14.6) 29 (19.6) 4 (12.5) 39 (18.4)
Tumor sizea 3.3 (0.6–19.5) 3.5 (0.7–17) .877b 3.15 (1.2–15) 3.5 (0.6–19.5)
Histologic grade .224c .286c
1, 2 48 (50) 61 (41.2) 11 (34.4) 98 (46.2)
3, 4 48 (50) 87 (58.8) 21 (65.6) 114 (53.8)
Large vessel invasion 11 (11.5) 13 (8.8) .642c 4 (12.5) 20 (9.4) .533d
Small vessel invasion 41 (42.7) 53 (35.8) .344c 13 (40.6) 81 (38.2) .946c
Prrx-1 positivity 12 (12.5) 20 (13.5) .972c 12 (37.5) 84 (39.6) .972c
Ki-67 indexe 21 (9–37.5) 22 (10–41) .754b 21 (9–35.5) 22 (9.5–40.5) .533b
Recurrence rate (%) < .001f .947f
1 Year 45.8 28.5 43.1 34.2
5 Years 78.1 57.1 71.2 64.8
Survival rate (%) .459f .409f
1 Year 88.3 86.8 77.5 88.9
5 Years 55.2 55.6 66.3 55.1
Values are presented as number (%) unless otherwise indicated.
Prrx-1, paired-related homeobox protein 1; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AJCC, American Joint Committee 
on Cancer.
aMedian (range); bMann-Whitney U test; cChi-square test; dFisher exact test; eMedian (first quantile–third quantile); fLog-rank test.
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= 19), and 29.8% of stage III (n = 11).
E-cadherin and Prrx-1 immunohistochemical staining 
results
E-cadherin expression was decreased in 96 cases (39.3%), wh-
ereas others showed moderate to strong membranous immuno-
reactivity. Thirty-two cases (13.3%) showed at least focal nucle-
ar Prrx-1 immunoreactivity. Loss of E-cadherin and Prrx-1 
expression was not concordant (p = .972 on the chi-square test). 
One hundred twenty cases showed minimally weak cytoplasmic 
stainability (49.2%). Cytoplasmic staining of Prrx-1 was not cor-
related with loss of E-cadherin expression (p = .217 on the chi-
square test).
All normal livers, including two whole section and one TMA 
section, of which there were twenty cases, were negative for Prrx-
1 staining. All Prrx-1 stainings with whole sections of three 
Prrx-1–positive HCCs and three Prrx-1–negative HCCs showed 
consistent results with the TMA stainings. All adjacent cirrhotic 
livers from the six sections were negative for Prrx-1.
 HCC biomarker relationships
We examined the correlation between Prrx-1 and E-cadherin 
immunohistochemical staining results and various clinicopath-
ological factors. HCCs with decreased E-cadherin tend to occur 
more frequently in the background of cirrhosis, compared to E-
cadherin maintained HCCs (88.5% vs 77.7%, p = .048 on the 
chi-square test). Both large vessel (portal vein, hepatic vein, or 
their major branches) invasion and small vessel invasion were 
more frequent in the E-cadherin reduced group compared with 
the maintained group; however, they were not statistically sig-
nificant (large vessel invasion: 11.5% vs 8.8%, p = .642 on chi-
square test; small vessel invasion: 42.7% vs 35.8%, p = .344 on 
chi-square test). Hepatitis B, hepatitis C, history of chronic al-
cohol intake, age, sex, pathologic stage, multiplicity of the tu-
mor, tumor size, and histologic grade were not significantly as-
sociated with E-cadherin expression (Table 2).
None of the factors were statistically significantly correlated 
with Prrx-1 expression and clinicopathological factors, although 
both large vessel invasion and small vessel invasion were more 
frequent in Prrx-1–positive HCCs (large vessel invasion: 12.5% 
vs 9.4%, p = .533; small vessel invasion: 40.6% vs 38.2%, p = 
.946) (Table 2). Prrx-1–positive HCCs showed more frequent 
p53 overexpression (25% vs 13.7%, p = .114 on chi-square test), 
although this result was not statistically significant. 
Survival analysis indicated that E-cadherin decreased HCCs 
that were identified in earlier recurrences than in E-cadherin 
Table 3. Association between E-cadherin and Prrx-1 expression as a combinational marker and clinicopathologic parameters in HCC pa-
tients (n = 244)
Parameter
E-cadherin positive E-cadherin negative
Prrx-1 positive (n = 20) Prrx-1 negative (n = 128) Prrx-1 positive (n = 12) Prrx-1 negative (n = 84)
AJCC stage
I 11 (55) 73 (57) 9 (75) 41 (48.8)
II 6 (30) 40 (31.2) 1 (8.3) 33 (39.3)
III 3 (15) 15 (11.7) 2 (16.7) 10 (11.9)
Multiplicity
Single 18 (90) 101 (78.9) 10 (83.3) 72 (85.7)
Multiple 2 (10) 27 (21.1) 2 (16.7) 12 (14.3)
Histologic gradea
1, 2 4 (20) 57 (44.5) 7 (58.3) 41 (48.8)
3, 4 16 (80) 71 (55.5) 5 (41.7) 43 (51.2)
Large vessel invasion 18 (90) 117 (91.4) 10 (83.3) 75 (89.3)
Small vessel invasion 10 (50) 85 (66.4) 9 (75) 46 (54.8)
Ki-67 indexb 26 (7.5–43.5) 21 (10–40.5) 21 (12.5–39) 21 (9–34.5)
Recurrence rate (%)
1 Year 60.1 73 51.1 54.6
5 Years 54.1 43 15.3 23.2
Survival rate (%)
1 Year 73.9 88.8 83.3 89
5 Years 54.6 56.9 83.3 51.7
Values are presented as number (%) unless otherwise indicated.
Prrx-1, paired-related homeobox protein 1; HCC, hepatocellular carcinoma; AJCC, American Joint Committee on Cancer.
aComparing both E-cadherin and Prxx-1 positive-group (the first column) to the others, the former showed significantly higher histologic grade (p = .037 on chi-
squared test); bMedian (first quantile–third quantile).
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Fig. 2. Kaplan-Meier curves for overall survival (A, C, E) and disease-free survival (B, D, F) in hepatocellular carcinomas according to Ameri-
can Joint Committee on Cancer stage, E-cadherin and paired-related homeobox protein 1 (Prrx-1) expression (log-rank test). 
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maintained HCCs (mean, 1.08 years vs 3.51 years; p < .001 on 
the log-rank test) (Fig. 2B). Within one year, 41 cases (45.8%) 
of E-cadherin decreased HCCs experienced recurrence, while 40 
cases of E-cadherin (28.5%) maintained HCCs did not. The 
overall survival rate was not significantly different on the log-
rank test (p = .459) (Fig. 2A). We also examined the correlation 
between patient’s survival/recurrence and Prrx-1 expression. Al-
though 1-year recurrence rate (43.1% vs 34.2%) and 5-year re-
currence rate (71.2% vs 64.8%) were higher in Prrx-1 that ex-
pressed HCCs than in Prrx-1–negative HCCs, the difference 
was not statistically significant on the log-rank test (p = .947) 
(Fig. 2D). Overall survival was also not significantly different (p = 
.408) (Fig. 2C).
We categorized HCCs into four groups, depending on the E-
cadherin and Prrx-1 expression. The clinicopathologic parame-
ters, recurrence rate, and survival rate were compared between 
Prrx-1–positive and Prrx-1–negative groups, and among E-cad-
herin–positive cases, in addition to the same comparison among 
E-cadherin–negative cases. Each of the four groups were also 
compared with the other three groups. The E-cadherin–positive 
and Prrx-1–positive group (n = 20) showed significantly higher 
nuclear grades than the rest of the group (n = 224) (nuclear 
grade 3 or 4 proportion: 80% vs 53.1%, p = .037 on chi-squared 
test). Other parameters in the various group comparison were 
not significantly different (Table 3, Fig. 2E and F).
Cox proportional hazard regression model
Factors that may affect the prognosis of HCC were filtered 
Univariate analysis Multivariate analysis 
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value Hazard ratio (95% CI) 
AJCC stage 
I vs. II 2.612 1.860–3.668 < .001 1.823 0.932–3.568 .079 
I vs. III 2.659 1.713–4.126 < .001 1.263 0.475–3.356 .640 
Cirrhosisa 1.583 0.984–2.547 .058 
Child-Pugh class (B) 1.026 0.502–2.099 .944 
Grade (3, 4) 0.927 0.622–1.381 .710 
Multiplicity 1.678 1.124–2.505 .011 1.329 0.798–2.215 .275 
Small vessel invasion 2.442 1.737–3.433 < .001 1.206 0.658–2.21 .545 
Large vessel invasion 4.512 2.780–7.322 < .001 3.633 1.444–9.139 .006 
E-cadherin loss 1.830 1.305–2.566 < .001 1.786 1.263–2.525 .001 
Prrx-1 positivity 1.018 0.603–1.717 .948 
Ki-67 index (≥ 40) 1.400 0.959–2.045 .082 
 1    2    3     4    5     6    7    8     9
Fig. 3. Cox proportional hazard regression model for disease-free survival. CI, confidence interval; AJCC, American Joint Committee on 
Cancer; Prrx-1, paired-related homeobox protein 1. aCirrhosis vs chronic hepatitis.
Univariate analysis Multivariate analysis 
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value Hazard ratio (95% CI) 
AJCC stage 
I vs. II 1.774 1.169–2.693 .007 1.266 0.616–2.602 .521 
I vs. III 2.465 1.373–4.424 .003 0.616 0.153–2.481 .496 
Cirrhosisa 2.406 1.315–4.403 .004 2.389 1.303–4.379 .005 
Child-Pugh class (B) 1.784 0.953–3.342 .071 
Grade (3, 4) 1.230 0.784–1.93 .367 
Multiplicity 1.084 0.651–1.804 .756 
Small vessel invasion 2.206 1.495–3.255 < .001 1.572 0.752–3.287 .230 
Large vessel invasion 2.988 1.687–5.290 < .001 3.379 0.853–13.381 .083 
E-cadherin loss 1.159 0.784–1.714 .458 
Prrx-1 positivity 1.278 0.713–2.292 .410 
Ki-67 index (≥ 40) 1.669 1.103–2.526 .015 1.583 1.045–2.399 .030
 1    2    3     4    5     6    7    8     9
Fig. 4. Cox proportional hazard regression model for overall survival. CI, confidence interval; AJCC, American Joint Committee on Cancer; 
Prrx-1, paired-related homeobox protein 1. aCirrhosis vs chronic hepatitis.
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for the multivariate Cox proportional hazard regression model 
(p < .05 in univariate Cox proportional hazard regression mod-
el). The disease-free and overall survival were separately pro-
cessed and are in Figs. 3 and 4, respectively. The stage, multi-
plicity, small and large vessel invasion, and decrease of E-cadherin 
were selected for factors in disease-free survival. Among them, 
the large vessel invasion (p = .006) and loss of E-cadherin (p = 
.001) were independent risk factors. The stage, cirrhosis, small 
and large vessel invasion, and high Ki-67 labeling index were 
selected for overall survival. Cirrhosis (p = .005) and high Ki-67 
labeling index (p = .030) were independent risk factors for over-
all survival.
DISCUSSION
EMT has an important role in cancer progression because it 
influences tumor cell migration, allows local tissue invasion, 
and into the blood vessel, which is a necessary step in cancer me-
tastasis.3 In colorectal cancer, tumor budding is one of the most 
important prognostic factors and reflects aggressive biologic be-
havior. The tumor budding is also explained as an EMT pro-
cess, consistently with its morphologic change to fibroblast-like 
appearance.13 E-cadherin is a type of cadherins, which is a type 
1 transmembrane protein, that plays an important role in cell 
adhesion. Loss of the E-cadherin is a hallmark of EMT and it is 
related to poor prognosis in various human cancers.14 In addition, 
several studies based on immunohistochemical staining of E-
cadherin have reported the prognostic significance of HCC.15-17 
Loss of E-cadherin is clearly associated with hematogenous 
tumor spread, lymph node metastasis, and local recurrence in 
various types of cancer, including breast cancer, colorectal can-
cer, and liver cancer.18-20 For HCC, Chen et al.18 performed a me-
ta-analysis to access the prognostic value of E-cadherin in HCC, 
and revealed that loss of E-cadherin was strongly associated 
with poor overall survival, recurrence-free survival, metastasis, 
vascular invasion, higher grade, and advanced TNM stage.18 As 
mentioned earlier, several other EMT inducers were evaluated 
as prognostic markers. SNAI1, an EMT inducer, was expressed 
in an invasive portion of HCC and was associated with the higher 
grade. Twist-1, another EMT inducer, was found to be associat-
ed with distant metastasis in HCC.21 
As previously mentioned, either upregulation or downregu-
lation of Prrx-1 has been reported to be associated with poor 
prognosis, depending on the type of cancer. In colorectal cancer, 
overexpression of PRRX1 mRNA was involved in metastasis 
and poor prognosis.7 In thyroid cancer, 57.7% of anaplastic thy-
roid carcinomas and two of five hobnail variants of papillary car-
cinoma, which are very aggressive and associated with high 
mortality rate, were positive for Prrx-1 on immunohistochemi-
cal staining, while all conventional papillary carcinomas were 
negative.4 In comparison, Ocana et al.5 found that loss of Prrx-1 
contributes to metastatic colonization and poor prognosis in 
breast cancer. They performed an experiment with a xenograft 
model, using human breast cancer cells that expressed both Prrx-
1 and Twist1. A knockdown of both Prrx-1 and Twist1 increased 
lung metastasis but not in a setting of only one knockdown. 
This indicated that downregulation of Prrx-1 is necessary to de-
velop metastatic nodules and gain proliferative activity.5 Simi-
larly, Hirata et al.8 studied mRNA expression level of Prrx-1 in 
HCC and found that the Prrx-1 downregulated group showed a 
poorer prognosis than the upregulated group. However, this 
study showed that normal livers did not express Prrx-1 protein 
immunohistochemically, and evokes a question that the decreased 
level of the PRRX1 mRNA has biological implications, as only 
a few (in our case, 13%) of the HCCs showed nuclear immuno-
reactivity on Prrx-1.
Ki-67 is a marker that reflects proliferative activity, which in-
creases during carcinogenesis. Poorly differentiated HCCs show 
a higher index of Ki-67 than in well- to moderately-differenti-
ated HCCs.22 In general, the proliferating activity decreases when 
tumor cells undergo EMT.23 We expected that loss of E-cad-
herin and expression of Prrx-1 would inversely correlate with 
the Ki-67 index. However, there was no significant difference, 
which was likely due to the limitation of a small number of Prrx-
1–positive cases and many other biological confounding vari-
ables that effect on the proliferation.
Through this study, we attempted to elucidate whether Prrx-
1–positive or Prrx-1–negative HCCs are associated with poor 
prognosis. As EMT is a dynamic process and its timely regula-
tion is necessary to metastasis, it is necessary to develop new 
markers to know whether the tumor will re-gain proliferative 
and epithelial property after hematogenous spread, when we ob-
serve E-cadherin loss in the resected primary tumor. However, 
we only validated E-cadherin as a useful prognostic factor to pre-
dict recurrence, and Prrx-1 was not correlated with patient’s prog-
nosis and recurrence. Our experiment had some limitations, 
which were attributable, in part to the role of Prrx-1 on the prog-
nosis of HCCs. The design of the present experiment did not 
implicate the complex mechanism of EMT–reverse EMT process 
during cancer metastasis. Cross-sectional studies using immuno-
histochemical staining on paraffin block have a limitation to 
dealing dynamic processes. Especially, as Prrx-1 is a transcription 
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factor, two assumptions are required for this immunohistochemi-
cal study: (1) the expression of Prrx-1 should be consistent 
through the time until E-cadherin molecules disappear in the cell 
membrane, and (2) the functional expression range and thresh-
old should be consistent with detection range and interpretation 
cutoff. However, many cellular signals work in a stochastic man-
ner and show oscillatory responses, which give an uncertainty to 
our assumption.24,25 Prrx-1 overexpression was observed in 
15.1% of HCCs in this study by immunohistochemistry. It is 
quite a small percentage comparing with 45.2% (28/62), which 
is the fraction of high-PRRX1 mRNA that expressed HCCs in 
the experiment by Hirata et al.8 We believe that this also gives 
an uncertainty to our second assumption.
In summary, Prrx-1 was expressed in small portion (13.3%) 
of HCCs but not in non-neoplastic livers. We validated that E-
cadherin loss had the prognostic value to predict recurrence in 
HCCs. Prrx-1 was not correlated with EMT nor prognosis nor 
recurrence by immunohistochemical staining study. Further 
study with a larger series of HCCs is required to elucidate the 
significance of Prrx-1 in HCCs.
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